Results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted, bispecific T-cell engager (BiTE (R)) immune therapy for metastatic castration-resistant prostate cancer (mCRPC)

Veröffentlicht vonadmin

Tran, B; Horvath, L; Dorff, T; Rettig, M; Lolkema, MP; Machiels, JP; Rottey, S; Autio, K; Greil, R; Adra, N; Lemech, C; Minocha, M; Cheng, FC; Kouros-Mehr, H; Fizazi, K

View this publication in the PUBMED database